XRCC1 and lung carcinoma: No other significant differences were detected with respect to the associations between predictive assessment in pharmacogenetics of XRCC1 genetic polymorphisms and the clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy (Tables 3 and 4).